3M Reaches Agreements to Sell its Pharmaceuticals Business
3M announced today that
it has entered into agreements to sell its global branded
pharmaceuticals business for approximately $2.1 billion in the
Graceway Pharmaceuticals Inc. has agreed to acquire 3M’s pharmaceutical operations in the United States, Canada, and Latin America region for $875 million.
Meda AB has agreed to acquire 3M’s pharmaceutical business in Europe for $857 million. The agreement will be implemented by each 3M subsidiary subject to compliance with third party notice and approval requirements.
Ironbridge Capital and Archer Capital have agreed to acquire 3M’s pharmaceutical operations in the Asia Pacific region, including Australia and South Africa for $349 million.
The agreements are the result of a review of strategic options for the branded pharmaceuticals business and its immune response modifier (IRM) platform that 3M announced in April. Under the agreements, the purchasers will acquire regional marketing and intellectual property rights for 3M’s well-known branded pharmaceuticals, including Aldara, Difflam, Duromine, Tambocor, Maxair, Metrogel-Vaginal and Minitran. 3M’s Drug Delivery Systems Division will be a source of supply to the acquiring companies for the products. As part of the transaction, Graceway Pharmaceuticals also will acquire the rights to certain IRM molecules.
3M serves customers through six business segments, which increase speed and efficiency by sharing technological, manufacturing, marketing and other resources.
These six businesses are:
Consumer and Office Business
With powerful brands, innovative products and a global presence, we make life easier and more productive for consumers and office workers around the world.
Display and Graphics
Drawing on 3M's technology platforms, we provide products - display enhancement films, reflective materials, eye-catching graphics and more - that people around the world rely on every day.
We turn 3M technology into solutions for customers in electrical, electronics and communications markets around the world. We contribute to reliable sources of electrical power, high-performance electronic devices, and speedy and dependable telecommunications networks globally.
Health Care Business
Every day, we help improve the quality of care provided by health care professionals throughout the world. Our innovative products and services also make the delivery of patient care more affordable.
We're a global leader in tapes, abrasives, adhesives, specialty chemicals, filtration systems, and software for supply chain management. We also serve the transportation market with products for the manufacture, repair and maintenance of autos, aircraft, boats and other vehicles.
Safety, Security and
Protection Services Business
Our products increase the safety, security and productivity of people, facilities and systems around the world. We’re also a leading supplier of roofing granules for asphalt shingles.
Immune Response Modifier (IRM)
3M Pharmaceuticals has a
rich product development pipeline based on the Immune Response
Modifier (IRM) technology platform. The IRMs are a class of
unique, proprietary synthetic molecules developed by 3M
Pharmaceuticals that have a broad range of potential therapeutic
applications, including promising treatments for a variety of
viruses and tumors.
Mechanism of Action
The IRMs are a new class of drug. They act by stimulating the body to produce cytokines, naturally occurring proteins used by cells of the immune system to communicate with each other. The cytokines induced by IRMs enhance cell-mediated immunity, a natural process by which the body controls or eliminates virus infected cells and tumor cells. Because the IRMs assist the immune system - rather than target specific viruses or tumors - they have potential uses in a wide variety of diseases. The IRMs can be formulated into many dose forms, each appropriate for a specific disease.
車用素材 米3M、日本に拠点 来年にも トヨタなどと開発